drugset / Trial / NCT00227032
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Phase 1
Terminated
10 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with progressive glioblastoma multiforme.
Timeline
- Start
- 2005-09
- Primary completion
- 2008-02
- Completion
- 2008-03
Outcome
Outcome not reported
Stopped (Business): “Loss of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Erlotinib | Small molecule | 300 mg | Oral |